ACCC refuses to approve pharma agreement in rare patent settlement request
Shutterstock/IgorGolovniov
Australia’s antitrust authority has voiced its concerns about a proposed patent dispute settlement and licensing agreement between Celgene and two drugmakers, warning that it could distort competition between generic manufacturers.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now